Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2020-11-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
北京德恒（昆明）律师事务所关于昆药集团2017年限制性股票激励计划首次授予部分第三期限售解除的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the third phase of lifting restrictions on shares granted under a 2017 restricted stock incentive plan of Kunming Pharmaceutical Group Co., Ltd. It details the approval and authorization process, conditions for lifting restrictions, the number of shares and persons involved, and legal compliance with relevant laws and regulations. The document is a standalone legal opinion related to stock incentive plan share restrictions and their lifting, not a full annual or interim financial report, earnings release, or management discussion. It is not a simple announcement but a detailed legal opinion on a specific corporate action related to share restrictions and stock incentives. This fits best under the category of Regulatory Filings (RNS) as it is a compliance/legal document that does not fit into other more specific categories like Capital/Financing Update or Director's Dealing. The document length (9619 characters) and content confirm it is not a brief announcement or a full financial report but a legal opinion. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2020-11-20 Chinese
关于聘任公司副总裁的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a new company vice president, including details about the individual's qualifications and the board's approval. It does not contain financial data, audit information, or report content. It is clearly about a change in senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on management appointment, confirming this classification.
2020-11-20 Chinese
关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Kunming Pharmaceutical Corporation regarding the approval of a clinical trial for a new drug (KY100001) by the National Medical Products Administration (国家药品监督管理局). It details the drug's basic information, research status, and potential impact on the company. The document is an announcement of a regulatory approval related to drug development, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document length is 1723 characters, which is relatively short and consistent with an announcement. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-11-12 Chinese
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of using temporarily idle raised funds to purchase financial products. It includes specifics about the entrusted financial products, amounts, risk control measures, approval procedures, and financial impacts. The document references regulatory approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange, details on fundraising amounts, and usage of funds. It is not a full financial report like an Annual Report or Interim Report, nor is it a simple announcement of a report publication. It is a regulatory announcement about capital management activities, specifically the use of idle raised funds for cash management through financial products. This fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage. The document length and detail support this classification with high confidence.
2020-11-05 Chinese
独立董事关于公司九届三十三次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Kunming Pharmaceutical Group Co., Ltd. regarding a specific board meeting agenda item about asset pledge financing. It references regulatory guidelines for independent directors and governance rules, and it provides an opinion on a financing proposal. The document is short (506 characters) and focuses on board-related matters rather than full financial data or report content. It is not a full audit report, annual report, or earnings release. It is not a simple announcement or certification but a formal opinion related to board decisions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board or senior management matters.
2020-10-21 Chinese
2020年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled '2020 年第三季度报告' which translates to '2020 Third Quarter Report'. It contains detailed financial data for the third quarter of 2020, including assets, liabilities, income, cash flows, shareholder information, and notes on significant events during the quarter. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the period. It is not a brief announcement or a certification letter, but a full interim financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2020
2020-10-21 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.